UK health regulator approves GSK’s vaccine for common respiratory virus RSV
(Reuters) -Britain’s health regulator approved GSK’s vaccine for the respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually, the drugmaker said on Monday.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorised GSK’s shot, called Arexvy, for active immunisation to prevent lower respiratory tract disease caused by RSV in adults 60 years and older, the company said.
RSV typically causes cold-like symptoms but is a leading cause of pneumonia in toddlers and the elderly.
The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.
Arexvy has recently got the green light from the United States and European regulators.
(Reporting by Eva Mathews in Bengaluru; Editing by Savio D’Souza and Dhanya Ann Thoppil)
Why pay for news and opinions when you can get them for free?
Subscribe for free now!
By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact